Keywords: degussa, buy, gilead, proligo, through, its, subsidiary
Degussa to buy 49% of Gilead's Proligo
Article | 23 August 2001
Through its US subsidiary, Germany's Degussa is to acquire a 49% stakein Gilead Sciences' Proligo joint venture for approximately $14 million in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
